NCT04792021

Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients

Effect of N-acetylcysteine on Oxidative Stress And Occurrence of Complications in Patients With COVID 19 Infections

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the potential therapeutic effect of N-acetylcysteine "NAC" in COVID 19 patients.

Detailed description

This is a phase 3 trial enrolling subjects with newly diagnosed Corona virus disease 2019 ( COVID-19) infection who are classified as moderate cases and require hospitalization. Patients meeting eligibility criteria will be randomized either to receive oral N-acetylcysteine or not along with the institution treatment protocol . Treatment efficacy will be assessed using certain endpoints as follows: 1. Markers of inflammation and oxidative stress 2. Length of hospital stay 3. Need for ventilation 4. Mortality rate

Conditions

• Corona Virus Disease 19 (Covid19)
• Corona Virus Infection
• Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)

Interventions

Type	Name	Description
DRUG	N-acetylcysteine	Oral formulation: 600 mg sachets of N-acetylcysteine

Timeline

• Start date: 2021-03-09
• Primary completion: 2021-09-13
• Completion: 2022-04-01
• First posted: 2021-03-10
• Last updated: 2022-04-27

Locations

1 site across 1 country: Egypt